Evidence map›Paper›PMID 41827060›Full record

ArticleAdvances in rheumatology (London, England)2026

Are global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients.

Lucas Castro Pires, Alisson Pugliesi, Cleandro Pires de Albuquerque, Vitor Alves Cruz, Manoel Barros Bertolo, Ana Paula Monteiro Gomides Reis, Rina Dalva Neubarth Giorgi, Leticia Rocha Pereira, Sebastião Cezar Radominski, Ivanio Alves Pereira and 7 more

Abstract read
In one paragraph

Article in Advances in rheumatology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lucas Castro PiresDepartment of Orthopedics, Rheumatology, and Traumatology, Universidade Estadual de Campinas (UNICAMP), R. Tessália Vieira de Camargo, 126 - Cidade Universitária, Campinas, SP CEP: 13083-887, Brazil. castrop@unicamp.br.ORCID http://orcid.org/0000-0002-6510-5925
Alisson PugliesiDepartment of Orthopedics, Rheumatology, and Traumatology, Universidade Estadual de Campinas (UNICAMP), R. Tessália Vieira de Camargo, 126 - Cidade Universitária, Campinas, SP CEP: 13083-887, Brazil.ORCID http://orcid.org/0000-0003-0444-738X
Cleandro Pires de AlbuquerqueDepartment of Rheumatology, Universidade de Brasília, Brasília, Brazil.ORCID http://orcid.org/0000-0002-9245-7504
Vitor Alves CruzDepartment of Rheumatology, Universidade Federal de Goiás, Goiania, Brazil.ORCID http://orcid.org/0000-0002-3073-2929
Manoel Barros BertoloDepartment of Orthopedics, Rheumatology, and Traumatology, Universidade Estadual de Campinas (UNICAMP), R. Tessália Vieira de Camargo, 126 - Cidade Universitária, Campinas, SP CEP: 13083-887, Brazil.ORCID http://orcid.org/0000-0002-0254-4330
Ana Paula Monteiro Gomides ReisDepartment of Rheumatology, Centro Universitário de Brasília (UniCEUB), Brasília, Brazil.ORCID http://orcid.org/0000-0003-2884-2210
Rina Dalva Neubarth GiorgiDepartment of Rheumatology, Hospital do Servidor Público Estadual de São Paulo (IASMPE), São Paulo, Brazil.ORCID http://orcid.org/0000-0002-0921-1723
Leticia Rocha PereiraDepartment of Social Medicine, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0002-9899-1695
Sebastião Cezar RadominskiDepartment of Rheumatology, Universidade Federal do Paraná, Curitiba, Brazil.ORCID http://orcid.org/0000-0001-6366-8401
Ivanio Alves PereiraDepartment of Rheumatology, Universidade Federal de Santa Catarina, Florianópolis, Brazil.ORCID http://orcid.org/0000-0002-3910-4988
Maria Fernanda Resende GuimarãesDepartment of Rheumatology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID http://orcid.org/0000-0003-3865-3739
Paulo Louzada JuniorDepartment of Rheumatology, Universidade de São Paulo, Ribeirão Preto, Brazil.ORCID http://orcid.org/0000-0003-2585-3870
Maria de Fátima Lobato da Cunha SaumaDepartment of Rheumatology, Universidade Federal do Pará, Belém, Brazil.ORCID http://orcid.org/0000-0003-0644-3139
Karina Rossi BonfiglioliDepartment of Rheumatology, Universidade de São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-3547-5674
Claiton Viegas BrenolDepartment of Rheumatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID http://orcid.org/0000-0003-0229-7912
Licia Maria Henrique da MotaDepartment of Rheumatology, Universidade de Brasília, Brasília, Brazil.ORCID http://orcid.org/0000-0002-8182-5121
Geraldo da Rocha Castelar PinheiroDepartment of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0002-7778-569X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population.

methodsWe conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0/2.0. Agreement was assessed using Cohen’s kappa, and optimal remission cut-offs were determined through ROC curve analysis.

resultsThe study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (κ = 0.775) and CDAI (κ = 0.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI ≤ 4.3 and CDAI ≤ 3.9, which increased remission detection by 5.9% and 6.2%, respectively.

conclusionIn our cohort, SDAI ≤ 4.3 and CDAI ≤ 3.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidSeverity of Illness IndexAdultAgedBrazilCross-Sectional StudiesFemaleHumansMaleMiddle AgedRemission InductionROC CurveAntirheumatic AgentsArthritisDisease activityPublic healthRheumatoidThreshold value

Identifiers

PMID41827060
PMCPMC13488623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.